Stromedix gets boost for lung-disease drug
Stromedix, Inc. has received word from the U.S. food and Drug Administration that its potential drug to treat a fatal lung disease will receive so-called orphan drug status. The designation carries several benefits for the company, including grants and/or tax incentives to help with drug development and a longer period of protection from generic competition, once the drug candidate is approved. Orphan drug status is designed to accelerate development of treatments for rare diseases. feeds.bizjournals.com |
Glendale may ban texting while driving
The city of Glendale is looking at following Phoenix’s lead with a ban on texting while driving. feeds.bizjournals.com |
Segundo Mine earns safety awards
Peabody Energy’s El Segundo Mine in northwestern New Mexico received three recognitions for safety excellence in September. (BTU) feeds.bizjournals.com |
Companies could be liable for outsourced work
Many things get outsourced in the technology world. That includes everything from management of computer networks and software development to the manufacture of components — even new product research and development. feeds.bizjournals.com |
ATSI posts loss for fiscal year 2010
ATSI Communications Inc. concluded the fiscal year with a net loss, despite ending the year with an increase in operating revenues. feeds.bizjournals.com |